Keith Flaherty
Director of Clinical Research, Mass General Brigham Cancer Institute · Mass General Brigham
Credentials: · · · ·
History
- Present
Mass General Brigham Cancer Institute Center
- Present
- 1993–1997
Research
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
New England Journal of Medicine · 2011 · 6,152 citations
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Science · 2016 · 3,807 citations
Final version of 2009 AJCC melanoma staging and classification
Journal of Clinical Oncology · 2009 · 3,581 citations
73 papers · 3 as a fellow
64 papers
55 papers
54 papers
49 papers · 28 as a resident
- DL
42 papers
- LH
37 papers
- SH
36 papers
Grants
- 2014–2027
Extension of the Dana Farber Harvard Cancer Center Consortium for the ETCTN
National Cancer Institute · UM1
PI · $25.9M · Dana-Farber Cancer Inst
- 2017–2022
An Integrated Translational Approach to Overcome Drug Resistance
National Cancer Institute · U54
PI · $6.3M · Massachusetts General Hospital
- 2011–2016
Role of Tumor Stroma in Therapeutic Response and Resistance
National Cancer Institute · U54
PI · $4.4M · University of Tx Md Anderson Can Ctr
- 2009–2014
Genotype and Phenotype Predictors in Therapy Response in Renal Cell Carcinoma
National Cancer Institute · R01
PI · $2.3M · University of Pennsylvania
Clinical trials
- 2015–2026
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
- 2012–2014
Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma
Principal investigator · Terminated · Phase 1
Massachusetts General Hospital
- 2008
Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
Principal investigator · Unknown · Phase 2
Abramson Cancer Center at Penn Medicine
- 2007–2017
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)